Revised forecast
Fiscal year ending March 2027 · Six months and full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The reason for revising the forecast is not stated. For the next fiscal year, the company assumes drug price revisions, issues relating to quality assurance and the stable supply of pharmaceuticals, inflation associated with geopolitical risks, and higher raw material costs, among other factors.
Goodwill impairment loss related to 三生医薬株式会社: ¥14,729 million
| Item | Details |
|---|---|
| Net Sales | Not disclosed → 2Q cumulative 145,700 / Full year 304,000 |
| Operating profit | Not disclosed → 2Q cumulative 12,700 / Full year 32,000 |
| Ordinary income | Not disclosed → 2Q cumulative 11,700 / Full year 30,000 |
| Profit attributable to owners of the parent | Not disclosed → 2Q cumulative 8,100 / Full year 21,500 |
| Net income per share | Not disclosed → 2Q cumulative 164.54 / Full year 436.75 |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Six months and full year |
| Previous-period results | Net Sales Fiscal year ended March 2026: ¥273,710 million / Operating profit Fiscal year ended March 2026: ¥23,102 million / Ordinary income Fiscal year ended March 2026: ¥28,079 million / Profit attributable to owners of the parent Fiscal year ended March 2026: ¥5,250 million / Net income per share Fiscal year ended March 2026: ¥106.66 |
| Reason for the revision | The reason for revising the forecast is not stated. For the next fiscal year, the company assumes drug price revisions, issues relating to quality assurance and the stable supply of pharmaceuticals, inflation associated with geopolitical risks, and higher raw material costs, among other factors. |
| Details and amount of extraordinary loss | Goodwill impairment loss related to 三生医薬株式会社: ¥14,729 million |
| Dividend forecast revision | For the fiscal year ending March 2027, the company forecasts an interim dividend of ¥40.00, a year-end dividend of ¥45.00, and an annual dividend of ¥85.00. It is not stated whether this represents a revision. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended March 2026, net sales increased on growth in sales volume and unit prices and stronger sales in Europe, while operating income declined due to a deterioration in the business mix at 三生医薬株式会社. Ordinary income increased, aided by a derivative valuation gain of ¥5,384 million. However, the company recorded a goodwill impairment loss of ¥14,729 million following the deterioration in 三生医薬株式会社's performance, resulting in a substantial decline in net income attributable to owners of the parent. For the fiscal year ending March 2027, the company assumes a challenging and uncertain environment, including drug price revisions, issues relating to quality assurance and stable supply, inflation associated with geopolitical risks, and higher raw material costs.